Compare Ascendis Pharma A/S (ASND) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs SkyWest Inc — how do they compare? Ascendis Pharma A/S trades at $263.91 (market cap $17.74B), while SkyWest Inc trades at $99.09 (market cap $3.96B). The key difference: Ascendis Pharma A/S is far larger — about 4.5× SkyWest Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SKYW | |
|---|---|---|
Market Cap | $17.74B | $3.96B |
Sector | Health | Technology |
52-Week High | $277.18 | $123.72 |
52-Week Low | $163.32 | $78.40 |
Enterprise Value | $18.11B | $5.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SkyWest (SKYW) trades at $99.72, down 0.29% on the day, with strong technical momentum showing bullish moving averages and key support at $98. The company maintains solid fundamentals with a P/E of 9.57, net income margin of 10.42%, and consistent earnings beats in recent quarters. Recent leadership changes include Wade Steel's promotion to President and COO of SkyWest Airlines.
SkyWest presents attractive valuation with upside to the $109.33 consensus price target, supported by strong analyst sentiment (56% buy ratings). Key risks include rising fuel costs highlighted in recent government data showing 84% year-over-year increases, which could pressure airline profitability despite current operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
